multitargeted antiangiogenic agent sunitinib (Pfizer Inc)
90
Structured Review
Pfizer Inc
multitargeted antiangiogenic agent sunitinib
Multitargeted Antiangiogenic Agent Sunitinib, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitargeted+antiangiogenic+agent+sunitinib/anti+angiogenic+drugs+sunitinib+sutent/pm23675882-63-6-13
Average 90 stars, based on 1 article reviews
Multitargeted Antiangiogenic Agent Sunitinib, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitargeted+antiangiogenic+agent+sunitinib/anti+angiogenic+drugs+sunitinib+sutent/pm23675882-63-6-13
Average 90 stars, based on 1 article reviews
multitargeted antiangiogenic agent sunitinib - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Activity Assay:Article Title: Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Article Snippet: Ovarian cancer (OC) carries a poor prognosis; however, accumulating molecular data for the major histologic subtypes may lead to subtype-specific treatment paradigms.. The present review discusses what is currently understood about the major molecular and histologic subgroups of OC.. Areas specifically addressed include hormonal pathways, tumor protein p53 (TP53) and AT rich interactive domain 1A (SWI-like; ARID1A) mutation, and the breast cancer 1/2, early onset (BRCA1/2) mutation/poly (ADP-ribose) polymerase 1 (PARP1), phosphatidylinositol-4,5-bisphosphate 3kinase, catalytic subunit alpha (PI3KCA)/v-akt murine thymoma viral oncogene homolog 1 (AKT1)/mechanistic target of rapamycin (MTOR), and mitogen-activated protein kinase kinase 1 and 2 (MAP2K1/2) pathways. |